Purdue's Sleep Aid Patents Are Obvious, Judge Rules

Law360, New York (March 30, 2015, 3:01 PM EDT) -- A New Jersey federal judge on Friday found that Purdue Pharmaceutical Products LP’s three patents for sleep aid Intermezzo are invalid for obviousness, granting a win to Actavis Elizabeth LLC, Novel Laboratories Inc. and others whom Purdue sued over plans to market their own generic versions of the drug.

In a two-page order, U.S. District Judge Jose L. Linares ruled that the asserted claims of U.S. Patent Numbers 8,252,809; 7,682,628; and 8,242,131 are invalid as obvious, removing an obstacle for defendants Actavis, Par Pharmaceuticals Inc., Dr. Reddy's Laboratories Inc., TWI Pharmaceuticals Inc. and Novel to go through the abbreviated new drug application...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS